- Home
- DRTS vs VYGR Comparison
DRTS vs VYGR Comparison
Compare DRTS & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRTS
- VYGR
- Stock Information
- Founded
- DRTS 2015
- VYGR 2013
- Country
- DRTS Israel
- VYGR United States
- Employees
- DRTS N/A
- VYGR N/A
- Industry
- DRTS Medical/Dental Instruments
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- DRTS Health Care
- VYGR Health Care
- Exchange
- DRTS Nasdaq
- VYGR Nasdaq
- Market Cap
- DRTS 211.7M
- VYGR 191.9M
- IPO Year
- DRTS N/A
- VYGR 2015
- Fundamental
- Price
- DRTS $2.85
- VYGR $3.26
- Analyst Decision
- DRTS Strong Buy
- VYGR Strong Buy
- Analyst Count
- DRTS 2
- VYGR 9
- Target Price
- DRTS $8.00
- VYGR $14.86
- AVG Volume (30 Days)
- DRTS 32.7K
- VYGR 303.5K
- Earning Date
- DRTS 05-19-2025
- VYGR 05-06-2025
- Dividend Yield
- DRTS N/A
- VYGR N/A
- EPS Growth
- DRTS N/A
- VYGR N/A
- EPS
- DRTS N/A
- VYGR N/A
- Revenue
- DRTS N/A
- VYGR $66,958,000.00
- Revenue This Year
- DRTS N/A
- VYGR N/A
- Revenue Next Year
- DRTS N/A
- VYGR $2.04
- P/E Ratio
- DRTS N/A
- VYGR N/A
- Revenue Growth
- DRTS N/A
- VYGR N/A
- 52 Week Low
- DRTS $1.75
- VYGR $2.75
- 52 Week High
- DRTS $4.39
- VYGR $9.55
- Technical
- Relative Strength Index (RSI)
- DRTS 54.02
- VYGR 44.21
- Support Level
- DRTS $2.57
- VYGR $3.46
- Resistance Level
- DRTS $3.00
- VYGR $3.54
- Average True Range (ATR)
- DRTS 0.16
- VYGR 0.19
- MACD
- DRTS 0.03
- VYGR -0.00
- Stochastic Oscillator
- DRTS 50.02
- VYGR 15.38
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.